Clinical trials in Chaidari – page 74

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Celgene Corp.

Contact Research Centre

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo

Greece

Participants:0–17 years
Substances:Somapacitan
Sponsor:Novo Nordisk A/S

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Sickle cell disease

Not recruiting

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Investigational

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Investigational

Greece

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational

Study on the Safety and Effectiveness of LT3001 for Patients with Acute Ischemic Stroke

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:LT3001
Sponsor:Lumosa Therapeutics Co. Ltd.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Celgene Corp.

Contact Research Centre

Hepatocellular carcinoma+14

Not recruiting

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:INCB099280
Sponsor:Incyte Corp.

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Methylprednisolone
Sponsor:Kezar Life Sciences Inc.

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries